Dr Jean-Baptiste Lattouf, MD

Professeur agrégé de clinique;
Chirurgie, faculté de médecine;
Université de Montréal, CRCHUM et
Institut du cancer de Montréal.

 

Mots clés : cancer du rein, génétique, biologie moléculaire, marqueurs, immunologie

 

 

Dr Lattouf a complété son éducation médicale en 1999 et sa spécialité en urologie en 2004 à la faculté de médecine de l’Université de Montréal. Après sa certification comme membre du Collège Royal des Médecin et Chirurgiens du Canada, il a complété une surspécialité en oncologie urologique en 2006 aux National Institutes of Health à Bethesda. Il a également complété une formation en chirurgie minimalement invasive en 2006 à Linz, en Autriche.

 

En pratique médicale depuis 2007 et investigateur au CR-CHUM depuis 2008, ses intérêts touchent à la biologie moléculaire, la génétique et l’immunologie du cancer du rein. Il est impliqué dans plusieurs essais cliniques dans le cancer du rein et de la prostate, et il administre une biobanque approuvée par le tumor repository network, laquelle a engendré plusieurs collaborations prolifiques ainsi que des publications dans le domaine du cancer rénal.

 

1999  MD, Université de Montréal, Faculté de médecine

2004 Diplôme d’études spécialisées, Université de Montéal, Faculté de médecine

2004  Liste d’honneur du Doyen

2008  Support salarial du Canadian Urological Association Stratup Fund (CUA-SF) 

2009  Support salarial du CUA-SF 

2008-2012 FRQS Chercheur boursier : Junior 1

Immunologie, biologie moléculaire et biomarqueurs dans le cancer du rein 

 

Site associé : 

  1. Page CRCHUM

 

 

  • 2007 (PI); CUA-abbott grant;
    "Le rôle de FKBP52 dans le cancer de la prostate"
  • 2010-2015 (co-PI) Institut de Recherche Terry Fox
    "Canadian Prostate Cancer Biomarker Network"
  • 2013-2016 (co-PI) Fondation Canadienne du Rein;
    "Immunologic signature linked to clinical outcome in kidney cancer patients: correlation with normal individuals and uremic/transplanted patients."
  1. Saad F, Winquist E, Hubay S, et al. Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2016;10:102-9.
  2. Kapoor A, Girard L, Lattouf JB, et al. Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). Urology 2016;89:19-26.
  3. Lavallee LT, Tanguay S, Jewett MA, et al. Surgical management of stage T1 renal tumours at Canadian academic centres. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2015;9:99-106.
  4. Yafi FA, Tanguay S, Rendon R, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urologic oncology 2014;32:31 e17-24.
  5. Yafi FA, Aprikian AG, Chin JL, et al. Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World journal of urology 2014;32:1295-301.
  6. Tholomier C, Bienz M, Hueber PA, et al. Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2014;8:195-201.
  7. Kapoor A, Dason S, Allard CB, et al. The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2014;8:E845-52.
  8. Fradet V, Mauermann J, Kassouf W, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urologic oncology 2014;32:839-45.
  9. Bishr M, Lattouf JB, Latour M, Saad F. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2014;8:E306-10.
  10. Bachir BG, Aprikian AG, Izawa JI, et al. Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. Urologic oncology 2014;32:441-8.
  11. Xu H, Lasso A, Guion P, et al. Accuracy analysis in MRI-guided robotic prostate biopsy. International journal of computer assisted radiology and surgery 2013;8:937-44.
  12. Williams AK, Kassouf W, Chin J, et al. Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urologic oncology 2013;31:1161-5.
  13. Reaume MN, Graham GE, Tomiak E, et al. Canadian guideline on genetic screening for hereditary renal cell cancers. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2013;7:319-23.
  14. North S, Basappa N, Bjarnason G, et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2013;7:238-43.
  15. Lattouf JB. Antibiotic use prior to transurethral resection of the prostate: Are we doing what we think we are doing? Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2013;7:E543.
  16. Fairey AS, Kassouf W, Estey E, et al. Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU international 2013;112:791-7.
  17. Fairey AS, Jacobsen NE, Estey E, et al. Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. European urology 2013;64:518-9.
  18. Bachir BG, Aprikian AG, Fradet Y, et al. Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2013;7:E667-72.
  19. Zorn KC, Trinh QD, Jeldres C, et al. Prospective randomized trial of barbed polyglyconate suture to facilitate vesico-urethral anastomosis during robot-assisted radical prostatectomy: time reduction and cost benefit. BJU international 2012;109:1526-32.
  20. Yafi FA, Aprikian AG, Fradet Y, et al. Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU international 2012;110:1317-23.
  21. Sandhu GS, Aprikian A, Chin J, et al. Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2012;6:E116-20.
  22. Saad F, Lattouf JB. Bisphosphonates: prevention of bone metastases in prostate cancer. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 2012;192:109-26.
  23. Power NE, Kassouf W, Bell D, et al. Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2012;6:E217-23.
  24. Metcalfe M, Kassouf W, Rendon R, et al. Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2012;6:455-62.
  25. Mason RJ, Kassouf W, Bell DG, et al. The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology 2012;79:840-5.
  26. Lau GJ, Godin N, Maachi H, et al. Bcl-2-modifying factor induces renal proximal tubular cell apoptosis in diabetic mice. Diabetes 2012;61:474-84.
  27. Kotb AF, Kovac E, Kassouf W, et al. Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? World journal of urology 2012;30:761-7.
  28. Jewett M, Finelli A, Kollmannsberger C, et al. Management of kidney cancer: canadian kidney cancer forum consensus update 2011. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2012;6:16-22.
  29. Fairey AS, Kassouf W, Aprikian AG, et al. Age >/= 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database. Urologic oncology 2012;30:825-32.
  30. Zorn KC, Widmer H, Lattouf JB, et al. Novel method of knotless vesicourethral anastomosis during robot-assisted radical prostatectomy: feasibility study and early outcomes in 30 patients using the interlocked barbed unidirectional V-LOC180 suture. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2011;5:188-94.
  31. Yafi FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU international 2011;108:539-45.
  32. Saad F, Hotte S, North S, et al. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17:5765-73.
  33. Letendre J, Saad F, Lattouf JB. Penile cancer: what's new? Current opinion in supportive and palliative care 2011;5:185-91.
  34. Lattouf JB, Fadlallah H, Saad F. Androgen deprivation and bone. Current osteoporosis reports 2011;9:20-4.
  35. Grange C, Letourneau J, Forget MA, et al. Phenotypic characterization and functional analysis of human tumor immune infiltration after mechanical and enzymatic disaggregation. Journal of immunological methods 2011;372:119-26.
  36. Chalasani V, Kassouf W, Chin JL, et al. Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2011;5:83-7.
  37. Bishr M, Lattouf JB, Gannon PO, Saad F. Updates on therapeutic targets and agents in castration-resistant prostate cancer. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2011;63:131-43.
  38. Sun M, Lughezzani G, Alasker A, et al. Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection. The Journal of urology 2010;183:970-5.
  39. Lughezzani G, Sun M, Perrotte P, et al. Comparative study of inguinal hernia repair rates after radical prostatectomy or external beam radiotherapy. International journal of radiation oncology, biology, physics 2010;78:1307-13.
  40. Lattouf JB, Saad F. Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Current opinion in urology 2010;20:247-52.
  41. Lattouf JB, Saad F. Bone health in nonmetastatic prostate cancer: what's the big deal? Current oncology 2010;17 Suppl 2:S49-54.
  42. Lattouf JB. Reflexive ordering of percent free PSA in patients: Do we need to ask the question? Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2010;4:321.
  43. Jeldres C, Sun M, Isbarn H, et al. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology 2010;75:315-20.
  44. Jeldres C, Lughezzani G, Sun M, et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. The Journal of urology 2010;183:1324-9.
  45. Bhojani N, Capitanio U, Suardi N, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. International journal of radiation oncology, biology, physics 2010;76:342-8.
  46. Zini L, Cloutier V, Isbarn H, et al. A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15:1013-8.
  47. Trinh QD, Saad F, Lattouf JB. The current management of small renal masses. Current opinion in supportive and palliative care 2009;3:180-5.
  48. Lattouf JB, Trinh QD, Saad F. The contemporary role of surgery in kidney cancer. Current oncology 2009;16 Suppl 1:S8-S15.
  49. Lattouf JB. Chemoprevention in bladder cancer: What's new? Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2009;3:S184-7.
  50. Jeldres C, Isbarn H, Capitanio U, et al. Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia. The Journal of urology 2009;182:626-32.
  51. Isbarn H, Jeldres C, Capitanio U, et al. Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy. Journal of endourology / Endourological Society 2009;23:1347-52.
  52. Godin-Ethier J, Pelletier S, Hanafi LA, et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. Journal of immunology 2009;183:7752-60.
  53. Singh AK, Krieger A, Lattouf JB, et al. Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. BJU international 2008;101:181-5.
  54. Lee SJ, Lattouf JB, Xanthopoulos J, Linehan WM, Bottaro DP, Vasselli JR. Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. European urology 2008;54:845-53.
  55. Lattouf JB, Beri A, D'Ambros OF, Grull M, Leeb K, Janetschek G. Laparoscopic partial nephrectomy for hilar tumors: technique and results. European urology 2008;54:409-16.
  56. Jeldres C, Suardi N, Walz J, et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. European urology 2008;54:1306-13.
  57. Beri A, Lattouf JB, Deambros O, et al. Partial nephrectomy using renal artery perfusion for cold ischemia: functional and oncologic outcomes. Journal of endourology / Endourological Society 2008;22:1285-90.
  58. Lattouf JB, Saad F. Preservation of bone health in prostate cancer. Current opinion in supportive and palliative care 2007;1:192-7.
  59. Lattouf JB, Jeschke S, Janetschek G. Laparoscopic retroperitoneal lymph node dissection: technique. BJU international 2007;100:1415-29.
  60. Lattouf JB, Grubb RL, 3rd, Lee SJ, et al. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU international 2007;99:1041-6.
  61. Lattouf JB, Beri A, Klinger CH, Jeschke S, Janetschek G. Practical hints for hemostasis in laparoscopic surgery. Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy 2007;16:45-51.
  62. Lattouf JB, Beri A, Jeschke S, Sega W, Leeb K, Janetschek G. Laparoscopic extended pelvic lymph node dissection for prostate cancer: description of the surgical technique and initial results. European urology 2007;52:1347-55.
  63. Lattouf JB, Srinivasan R, Pinto PA, Linehan WM, Neckers L. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nature clinical practice Urology 2006;3:590-601.
  64. Lattouf JB, Arlen PM, Pinto PA, Gulley JL. A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy. Clinical genitourinary cancer 2006;5:89-92.
  65. Lattouf JB, Mc Cormack M, Yelle L, Hadjeres R, Saad F. Recurrence of a non-seminomatous germ cell tumor in the seminal vesicle 20 years after initial diagnosis and treatment. The Canadian journal of urology 2004;11:2350-1.
  66. Saad F, Lattouf JB. A digital rectal examination after radical prostatectomy is unnecessary if prostate specific antigen is undetectable. BJU international 2003;91:887-8.
  67. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU international 2003;91:417-20.
  68. Lattouf JB, Saad F. Digital rectal exam following prostatectomy: is it still necessary with the use of PSA? European urology 2003;43:333-6.
  69. Lattouf JB, Saad F. Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU international 2002;90:694-8; discussion 8-9.